02.02.26 -- The Top Drug Development Partners Talk A Good Game

Taking a molecule from drug substance to drug product often falters at the handoff. In this webinar, KBI Biopharma and Argonaut Manufacturing Services share how integrated CDMO-to-fill-finish partnerships eliminate silos, streamline quality, and reduce risk. Join a candid fireside chat on the top 10 quality challenges and proven solutions that cut timelines by 2–3 months from development through late-stage commercialization. Click here to learn more.

CDMO selection requires evaluating experience, quality standards, and flexibility. Assess technical transfer skills, supply chain security, and collaborative approach for a reliable, long-term project fit.

Integrating linear expression technology into single B cell workflows accelerates antibody discovery, enabling early functional screening, improved sensitivity, and cost-effective identification.

Recognizing and integrating diversity, equity, and inclusion (DEI) is essential for fostering innovation, improving team performance, and ensuring long-term competitiveness in a global market.

Turn enterprise resource management (ERM) from a checklist into a true decision system, so risk informs everyday choices before quality events become supply disruptions, delays, or regulatory exposure.

Discover how next-generation inhalation technologies can transform pulmonary drug delivery and unlock new therapeutic possibilities for a wide range of respiratory diseases.

AI-powered predictive maintenance with wireless vibration sensors prevented costly loss and production shutdowns in pharma manufacturing by detecting and fixing equipment issues before failures occurred.

Explore a structured approach to optimizing and scaling plasmid DNA production using E. coli, with insights into key growth parameters, benchtop feasibility, and pilot-scale performance.

Delve into a comprehensive overview of the challenges, requirements, and best practices for safely working with highly potent compounds in drug development and manufacturing.

The complex biology of rare diseases creates unique hurdles, making it difficult to design and implement a drug development program. See the unique considerations for drug product manufacturing.

Review the development of a high-strength synthetic gene promoter that enhances titers while maintaining product quality and expression stability, to support more efficient biomanufacturing.

Learn how adopting a risk-based validation strategy across global sites can reduce operational readiness timelines and drive improvements in equipment effectiveness and regulatory compliance.

Join Outsourced Pharma Chief Editor Jeff Buguliskis and our panel of industry experts as they share practical advice, reveal what to look for beyond the surface, and answer your toughest questions about selecting a CDMO partner that can truly deliver. Register for free today!

Overcome capacity constraints, regulatory complexities, and geopolitical risks to deliver exceptional scale, speed, supply-chain agility, and resilience.

With extensive experience and capabilities, we foster a collaborative environment, developing and implementing innovative analytical methods to efficiently address the testing needs of our partners.

Look at end-to-end services offered by a trusted CDMO partner with more than 15 years of industry-leading experience in conjugation and purpose-built manufacturing facilities.

Absorb how our parallel development service works seamlessly with our existing antibody capabilities, helping to accelerate your ADC program and reach market faster.

Join Boehringer Ingelheim in driving innovation, sustainability, and healthcare advancements in China, creating a healthier future for humans and animals alike.